Synthesis of N, N-Bis(dialkoxyphosphinoylmethyl)- and N, N-Bis(diphenylphosphinoylmethyl)- β - and γ -amino acid Derivatives by the Microwave-Assisted Double Kabachnik–Fields Reaction

Erika Bálint,¹ Eszter Fazekas,² János Kóti,³ and György Keglevich²

¹MTA-BME Research Group for Organic Chemical Technology, 1521 Budapest, Hungary

²Department of Organic Chemistry and Technology, Budapest University of Technology and Economics, 1521 Budapest, Hungary

³Gedeon Richter Plc., 1475 Budapest 10, Hungary

Received 28 May 2014; revised 23 July 2014

ABSTRACT: The title compounds were synthesized by the microwave-assisted, mostly solvent-free bis Kabachnik–Fields condensation of β -alanine and γ -aminobutyric acid or their esters with formaldehyde and >P(O)H species, such as dialkyl phosphites and diphenylphosphine oxide. © 2014 Wiley Periodicals, Inc. Heteroatom Chem. 00:1–10, 2014; View this article online at wileyonlinelibrary.com. DOI 10.1002/hc.21221

INTRODUCTION

The Kabachnik–Fields reaction is an important tool for the synthesis of α –aminophosphonates and re-

Contract grant number: OTKA No K83118 and PD111895. Contract grant sponsor: National Excellence Programme.

Contract grant sponsor: National Excellence Programme. Contract grant number: TÁMOP 4.2.4.A/1-11-1-2012-0001.

Supporting Information is available in the online issue at www.wileyonlinelibrary.com.

© 2014 Wiley Periodicals, Inc.

lated derivatives [1–5] that are of real or potential biological activity [3,6–8]. With regard to the synthesis, a number of catalytic versions were described including microwave (MW)-assisted variations [9, 10]. It was suggested that under solvent-free and MW-assisted conditions, there is no need for any catalyst [11]. α - and β -Amino acids may also be the starting materials for the Kabachnik–Fields reaction [12–14].

As a significant modification, the double Kabachnik–Fields reaction was also elaborated to make available bis(phosphonomethyl)amine derivatives [15–18]. The bis(phosphinoylmethyl)amines are valuable intermediates as they may be converted to bisphosphine ligands after double deoxygenation [16–18].

It is also possible to prepare bis(phosphinoylmethyl) derivatives from amino acids or their esters by the double Kabachnik–Fields reaction. A few studies appeared on the synthesis of bis derivatives from α -amino acids or esters [19–22]. The bis(Kabachnik–Fields) reaction was utilized in the synthesis of an *N*,*N*-bis(dimethoxyphosphinoylmethyl)- γ -aminobutyric acid applying the reagents in an excess, and using tetrahydrofuran as the solvent

Correspondence to: György Keglevich; e-mail: gkeglevich@ mail.bme.hu.

Contract grant sponsor: Hungarian Scientific and Research Fund.

2 Bálint et al.

26 °C/12 h $HO_2C(CH_2)_3NH_2 + HCHO +$ HP(O)(OMe)₂ HO₂C(CH₂)₃N(CH₂P(O)(OMe)₂)₂ THF (aq.) 3 equiv. 4 eqiuv. 53% SCHEME 1 [23] 110–120 °C/1 h $RO_2C(CH_2)_nN(CH_2OBu)_2 + 2 HP(O)(OEt)_2$ RO₂C(CH₂)_nN(CH₂P(O)(OEt)₂)₂ 2 BuOH R Et Me n 2 3 SCHEME 2 [24] ∆, 2 h ZnCl₂ pyridine (Me₃Si)₂NH $HO_2C(CH_2)_nNH_2 + 2 HCHO + 2 HP(O)(OEt)_2$ HO₂C(CH₂)_nN(CH₂P(O)(OEt)₂)₂ - NH₂ BuOH – 2 H₂O Me₃SiO₂C(CH₂)_nN(CH₂P(O)(OEt)₂)₂ HO₂C(CH₂)_nN(CH₂P(O)(OEt)₂)₂ n = 2.3 diethyl ether MeOSiMe₃ SCHEME 3 [24] 2 HCHO + 2 HPPh $HO_2C(CH_2)_nN(CH_2PPh_2)_2 \xrightarrow{H_2O_2} HO_2C(CH_2)_nN(CH_2P(O)Ph_2)_2$ HO₂C(CH₂)_nNH₂ + 2 HOCH₂PPh₂ -MeOH - 2 H₂O **SCHEME 4** [25]

(Scheme 1) [23]. Other derivatives, such as *N*,*N*-bis-(diethoxyphosphinoylmethyl)- γ -aminobutyric acid or β -aminopropionic acid derivatives, were synthesized by somewhat related or different approaches suggested by Prishchenko (Schemes 2 and 3) [24]. Scheme 2 shows a method comprising a double nucleophilic substitution, whereas Scheme 3 involves a double Kabachnik-Fields reaction that is followed by the temporary derivatization of the bissubstituted aminobutvric and aminopropionic acids to obtain pure bis(diethoxyphosphinoylmethyl)amino acids as the final products [24]. N,N-Bis-(diphenylphosphinoylmethyl)-y-aminobutyric acid and the analogous β -aminopropionic acid were made available by a special method utilizing the diphenylphosphine formaldehyde adduct in the double *N*-alkylation of the amino acids (Scheme 4) [25].

In this article, we describe the synthesis of the bis(phosphinoyl) derivatives of β -alanine and γ -aminobutyric acid and their esters by the double Kabachnik–Fields condensation.


RESULTS AND DISCUSSION

MW-Assisted Synthesis of β *- and* γ *-Amino Acid Derivatives*

First, the double Kabachnik–Fields reaction of β -alanine (1) and its methyl and ethyl esters (2

and 3) with 2 equiv of paraformaldehyde and 2 equiv of dialkyl phosphites, such as dimethyl phosphite, diethyl phosphite, dibutyl phosphite, and dibenzyl phosphite, was investigated under MW conditions. The methyl and ethyl esters of β alanine (2 and 3) were liberated from the corresponding hydrochloride salts prior to the reaction. The condensations were performed at 100°C for 1 h in the absence of any solvents, and the expected N,N-bis(dialkoxyphosphinovlmethyl)- β -alanine derivatives (**4a–d**, **5a–d**, and **6a–d**) were obtained in yields of 70-99% after column chromatography (Scheme 5 and Table 1). Using diphenylphosphine oxide as the P reagent, the reactions were carried out in acetonitrile to overcome the heterogeneity of the reaction mixture. After a 1 h irradiation at 100°C, flash chromatography afforded the bis(diphenylphosphinoylmethyl) derivatives 7, 8, and 9 in yields of 61–89% (Scheme 6 and Table 1).

In the next round, γ -aminobutyric acid (10) and its methyl and ethyl esters (11 and 12) were reacted with 2 equiv of paraformaldehyde and the same amount of dialkyl phosphites. After an irradiation of 1 h at 100°C, the corresponding products 13a–d, 14a–d, and 15a–d were obtained in yields of 60–97% (Scheme 7 and Table 2). The similar reaction of diphenylphosphine oxide afforded the



SCHEME 5 Double Kabachnik–Fields reaction of β -alanine derivatives, paraformaldehyde, and dialkyl phosphites.

TABLE 1 Yields of the $Bis(>P(O)CH_2)-\beta$ -alanine Derivatives


Entry	Compound	Yield (%)	Compound	Yield (%)	Compound	Yield (%)
1	4a	70	5a	73	6a	76
2	4b	85	5b	95	6b	87
3	4c	77	5c	90	6c	77
4	4d	96	5d	99	6d	91
5	7	61	8	89	9	85

TABLE 2 Yields of the Bis(>P(O)CH₂)- γ -aminobutyric Acid Derivatives


		Yield		Yield		Yield
Entry	Compound	(%)	Compound	(%)	Compound	(%)
1	13a	79	14a	86	15a	74
2	13b	76	14b	89	15b	96
3	13c	77	14c	93	15c	79
4	13d	81	14d	88	15d	97
5	16	60	17	94	18	80


bis(diphenylphosphinoylmethyl) derivatives **16**, **17**, and **18** in 60, 89, and 80% yields, respectively. These reactions had to be also carried out in acetonitrile due to the heterogeneity (Scheme 8 and Table 2).

It was found that in the reaction of γ -aminobutyric acid (10) or its ethyl ester (12), paraformaldehyde, and diphenyl phosphine oxide, a ring by-product, *N*-diphenylphosphinoylmethyl)-2-pyrrolidinone (19), was formed that was isolated in 18% and 35%, respectively.





The analogous by-products were also found to have been formed in small quantities (5–-10%) in the condensation of γ -aminobutyric acid (10) or its esters (11 and 12), paraformaldehyde, and dialkyl phosphites. The pyrrolidinone-type by-products may be formed in two ways. The first possibility is that





 $\begin{array}{c} CO_{2}R^{1} \\ & \\ NH_{2} \\ \hline \\ NH_{2} \\ \hline \\ R^{1} \\ H \\ H \\ H \\ Et \\ I2 \end{array} + 2 (HCHO)_{n} + 2 (R^{2}O)_{2}P(O)H \xrightarrow{MW}_{100 \ ^{\circ}C, 1 \ h}_{no \ solvent} R^{1}O_{2}C-CH_{2}-CH_{2}-CH_{2}-N \\ \hline \\ R^{1}O_{2}C-CH_{2}-CH_{2}-CH_{2}-N \\ CH_{2}-P(OR^{2})_{2} \\ CH_{2}-P(OR^{2$





SCHEME 8 Double Kabachnik–Fields reaction of γ -aminobutyric acid derivatives, paraformaldehyde, and diphenylphosphine oxide.

the amino acid is dehydrated to the lactam prior to the Kabachnik-Fields reaction (Route 1). The other possibility is that the α -aminophosphine oxide $[R^1O_2C(CH_2)_3NHCH_2P(O)Ph_2(20)]$ or α -aminophosphonate $[R^1O_2C(CH_2)_3NHCH_2P(O)(OR)_2$ (21)] intermediate formed in the first stage undergoes cyclization (Route 2). The possibility for Route 1 was investigated by a separate experiment involving the attempted cyclization of ethyl γ -aminobutyrate (12) under MW irradiation at 100°C for 1 h. ¹H NMR analysis revealed that 18% of the amino acid ester 12 was cyclized. It is worth mentioning that γ -aminobutyric acid (10) was more reluctant in respect of cyclization. In the reaction of 10 at 100°C for 1 h in a few drops of acetonitrile (to ensure a homogeneous medium), only a small (<3%) quantity of the pyrrolidinone could be pointed out by ¹H NMR analysis. From the above data, one can see that Route 2 may become predominant in respect of the formation of the ring by-product via the α -aminophosphine oxide $[R^1O_2C(CH_2)_3NHCH_2P(O)Ph_2$ (20)] intermediate. If R^1 = alkyl, the cyclization is more preferred, as compared to the case, when $R^1 = H$.

Comparative Thermal Experiments

Comparative thermal experiments were also performed in a few cases to evaluate the potential of MW irradiation in the above syntheses. The double Kabachnik–Fields reactions of β –alanine (1), or γ – aminobutyric acid (10), or their esters (2, 3 and 11, 12), paraformaldehyde, and diethyl phosphite were repeated under conventional heating at 100°C for 1 h in sealed tubes. The yields of the thermal control experiments were 7–39% lower, indicating the positive role of MW irradiation (Table 3). The acceleration observed on MW irradiation is the consequence of the beneficial effect of the local overheatings occurring statistically in the bulk of the mixture [26]. The detailed study of this effect in organophosphorus reactions means a challenge for us [27].

It is worth mentioning that in the reaction of γ -aminobutyric acid derivatives (10-12),

TABLE 3	Yields of the MW-Assisted and Comparative Ther-
mal React	ions

		Yield (%)		
Entry	Compound	MW	Δ	
1	4b	85	70	
2	5b	95	81	
3	6b	87	80	
4	13b	76	54	
5	14b	89	63	
6	15b	96	57	

paraformaldehyde, and diethyl phosphite carried out on conventional heating, a small proportion (<7%) of the pyrrolidinone-type by-products was always present. This confirms that the lactam byproduct may be formed both under MW and conventional heating. The direct cyclization of γ aminobutyric acid (**10**) to 2-pyrrolidinone involves a 5-h reflux in toluene in the presence of Al₂O₃ as the dehydrating agent [28].

In summary, 30 trifunctionalized amines, comprising bis(dialkoxyphosphinoylmethyl)- or bis(diphenylphosphinoylmethyl)- β - and γ -amino acid derivatives, were synthesized under MW and, in most cases, solvent-free conditions. Among the compounds, 25 are new and two were characterized partially earlier. The accelerating effect of the MW technique was demonstrated by comparative thermal experiments.

EXPERIMENTAL

General

The ³¹P, ¹³C, and ¹H NMR spectra were obtained in CDCl₃ solution on a Bruker AV-300 spectrometer operating at 121.5, 75.5, and 300 MHz, respectively. Chemical shifts are downfield relative to 85% H₃PO₄ and tetramethylsilane. Mass spectra were obtained using a Thermo LTQ-FT-Ultra mass spectrometer. The reactions were carried out in a 300 W CEM Discover focused MW reactor equipped with a pressure controller, applying 20–30 W under isothermal conditions.

The β -alanine and γ -aminobutyric acid esters were liberated from their hydrochloride salts using 20% Na₂CO₃ solution (2.0 g of Na₂CO₃ and 8 mL of water). Dichloromethane (2 × 10 mL) was used for the extraction of the free base. The organic phase was separated and dried (Na₂SO₄). Evaporation of the volatile components provided the β -alanine and γ -aminobutyric acid esters.

General Procedure for the Preparation of $Bis(>P(O)CH_2)-\beta$ -alanines (**4**) and $Bis(>P(O)CH_2)-\beta$ -alanine Esters (**5** and **6**)

A mixture of 1.70 mmol β -alanine or its esters (β alanine: 0.15 g, β -alanine methyl ester: 0.18 g, or β -alanine ethyl ester: 0.20 g), 0.10 g (3.40 mmol) of paraformaldehyde, and 3.40 mmol of the >P(O)H species (dimethyl phosphite: 0.31 mL, diethyl phosphite: 0.44 mL, dibutyl phosphite: 0.67 mL, and dibenzyl phosphite: 0.75 mL) was heated at 100°C in a vial in the MW reactor equipped with a pressure controller for 1 h. Then, the water formed was removed in a vacuum. Column chromatography (silica gel 3% methanol in dichloromethane) of the residue afforded the products (**4a–d**, **5a–d**, **6a–d**) as oils. The following products were thus prepared.

N,*N*-*Bis*(*dimethoxyphosphonylmethyl*)-*β*-*alanine* (**4a**). Yield: 70% (0.40 g); ³¹P NMR (CDCl₃) δ: 25.2; ¹³C NMR (CDCl₃) δ: 33.0 (*C*H₂C=O), 49.3 (dd, ¹*J*_{CP} = 157.1, ³*J*_{CP} = 6.0, CH₂P), 52.7 (t, ²*J*_{CP} = 3.0, CH₂N), 52.8 (t, ³*J*_{CP} = 3.5, OCH₃), 174.1 (C=O); ¹H NMR (CDCl₃) δ: 2.53 (t, ³*J*_{HH} = 6.7, 2H, CH₂C=O), 3.14 (t, ³*J*_{HH} = 6.5, 2H, CH₂N), 3.22 (d, ²*J*_{PH} = 8.8, 4H, CH₂P), 3.79 (d, 12H, ²*J*_{PH} = 10.3, OCH₃); [M + H]⁺_{found} = 334.0804, C₉H₂₂NO₈P₂ requires 334.0815.

N, N-Bis(diethoxyphosphonylmethyl)- β -alanine

(4b). Yield: 85% (0.56 g); ³¹P NMR (CDCl₃) δ : 25.3; δ [24] (CDCl₃) 22.1; ¹³C NMR (CDCl₃) δ : 16.3 (t, ³ J_{CP} = 2.7, CH₂CH₃), 33.0 (CH₂C=O), 50.1 (dd, ¹ J_{CP} = 156.6, ³ J_{CP} = 6.0, CH₂P), 52.7 (t, ³ J_{CP} = 6.6, CH₂N), 62.3 (t, ² J_{CP} = 3.3, OCH₂), 174.0 (C=O); δ [24] (CDCl₃) 49.63 (dd, ¹ J_{CP} = 155.4, ³ J_{CP} = 5.9, CH₂P), 52.16 (t, ³ J_{CP} = 7.2, CH₂N), 173.53 (C=O); ¹H NMR (CDCl₃) δ : 1.29 (t, ³ J_{HH} = 6.8, 12H, CH₂CH₃), 2.48 (t, ³ J_{HH} = 6.3, 2H, CH₂C=O), 3.11 (t, ³ J_{HH} = 6.1, 2H, CH₂N), 3.16 (d, ² J_{PH} = 8.7, 4H, CH₂P), 4.04–4.17 (m, 8H, OCH₂); δ [24] (CDCl₃) 2.94 (t, ³ J_{HH} = 7.2, 2H, CH₂N), 3.01 (d, ² J_{PH} = 8.8, 4H, CH₂P); [M + H]⁺_{found} = 390.1447, C₁₃H₃₀NO₈P₂ requires 390.1441. *N*,*N*-*Bis*(*dibutoxyphosphonylmethyl*)-*β*-*alanine* (**4c**). Yield: 77% (0.66 g); ³¹P NMR (CDCl₃) δ: 24.7; ¹³C NMR (CDCl₃) δ: 13.5 (CH₃), 18.7 (CH₂CH₂CH₂CH₃), 32.5 (t, ³*J*_{CP} = 2.9, OCH₂CH₂), 33.3 (CH₂C=O), 50.0 (dd, ¹*J*_{CP} = 155.6, ³*J*_{CP} = 5.3, CH₂P), 53.0 (t, ³*J*_{CP} = 6.4, CH₂N), 66.0 (t, ³*J*_{CP} = 3.5, OCH₂CH₂), 174.0 (C=O); ¹H NMR (CDCl₃) δ: 0.92 (t, ³*J*_{HH} = 7.4, 12H, CH₃), 1.32–1.41 (m, 8H, O CH₂CH₂CH₂), 1.58–1.66 (m, 8H, OCH₂CH₂), 2.50 (t, ³*J*_{HH} = 6.7, 2H, CH₂C=O), 3.13 (t, ³*J*_{HH} = 6.7, 2H, CH₂N), 3.21(d, ²*J*_{PH} = 8.3, 4H, CH₂P), 4.00–4.15 (m, 8H, OCH₂); [M + H]⁺_{found} = 502.2690, C₂₁H₄₆NO₈P₂ requires 502.2693.

N,*N*-*Bis*(*dibenzylyoxyphosphonylmethyl*)- β *alanine* (**4d**). Yield: 96% (1.04 g); ³¹P NMR (CDCl₃) δ : 25.4; ¹³C NMR (CDCl₃) δ : 33.4 (*C*H₂C=O), 50.6 (dd, ¹*J*_{CP} = 154.7, ³*J*_{CP} = 4.7, CH₂P), 53.1 (t, ³*J*_{CP} = 2.7, CH₂N), 67.8 (t, ³*J*_{CP} = 3.2, OCH₂), 128.1 (C₃),* 128.5 (C₄), 128.6 (C₂),* 135.9 (t, ³*J*_{CP} = 2.7, C₁), 173.9 (C=O), *may be reversed; ¹H NMR (CDCl₃) δ : 2.39–2.48 (m, 2H, CH₂C=O), 3.15 (d, ²*J*_{PH} = 8.1, 4H, .CH₂P), 3.90 (t, ³*J*_{HH} = 5.6, 2H, CH₂N), 4.91–5.04 (m, 8H, OCH₂), 7.28–7.39 (m, 20H, ArH); [M + H]⁺_{found} = 638.2062, C₃₃H₃₈NO₈P₂ requires 638.2067.

N,*N*-*Bis*(*dimethoxyphosphonylmethyl*)-*β*-*alanine Methyl Ester* (**5a**). Yield: 73% (0.43 g); ³¹P NMR (CDCl₃) δ: 26.9; ¹³C NMR (CDCl₃) δ: 32.8 (*C*H₂C=O), 49.2 (dd, ¹*J*_{CP} = 156.1, ³*J*_{CP} = 5.9, CH₂P), 51.6 (COOCH₃), 52.4 (t, ³*J*_{CP} = 7.7, CH₂N), 52.6 (t, ²*J*_{CP} = 3.4, OCH₃), 172.3 (C=O); ¹H NMR (CDCl₃) δ: 2.53 (t, ³*J*_{HH} = 7.0, 2H, CH₂C=O), 3.14 (t, ³*J*_{HH} = 6.9, 2H, CH₂N), 3.22 (d, ²*J*_{PH} = 8.7, 4H, CH₂P), 3.68 (s, 3H, COOCH₃), 3.78 (d, 12H, ²*J*_{PH} = 10.4, OCH₃); [M + H]⁺_{found} = 348.0968, C₁₀H₂₄NO₈P₂ requires 348.0972.

N,*N*-*Bis*(*diethoxyphosphonylmethyl*)- β -*alanine Methyl Ester* (**5b**). Yield: 95% (0.65 g); ³¹P NMR (CDCl₃) δ : 24.6; ¹³C NMR (CDCl₃) δ : 16.4 (t, ³*J*_{CP} = 2.8, CH₂CH₃), 32.9 (CH₂C=O), 50.0 (dd, ¹*J*_{CP} = 155.3, ³*J*_{CP} = 5.7, CH₂P), 51.5 (COOCH₃), 52.3 (t, ³*J*_{CP} = 7.5, CH₂N), 61.9 (t, ²*J*_{CP} = 3.4, CH₂CH₃), 172.4 (C=O); ¹H NMR (CDCl₃) δ : 1.33 (t, ³*J*_{HH} = 7.0, 12H, CH₂CH₃), 2.54 (t, ³*J*_{HH} = 7.2, 2H, CH₂C=O), 3.16 (t, ³*J*_{HH} = 7.1, 2H, CH₂N), 3.20 (d, ²*J*_{PH} = 8.4, 4H, CH₂P), 3.67 (s, 3H, COOCH₃), 4.09–4.18 (m, 8H, OCH₂); [M + H]+_{found} = 404.1593, C₁₄H₃₂NO₈P₂ requires 404.1598.

N,*N*-*Bis*(*dibutoxyphosphonylmethyl*)-β-alanine Methyl Ester (**5c**). Yield: 90% (0.79 g); ³¹P NMR (CDCl₃) δ: 24.8; ¹³C NMR (CDCl₃) δ: 13.5 (CH₂ CH₂CH₂CH₃), 18.7 (CH₂CH₂CH₂CH₃), 32.5 (t, ³J_{CP}) = 2.9, OCH₂CH₂), 32.9 (CH₂C=O), 49.9 (dd, ${}^{1}J_{CP}$ = 154.7, ${}^{3}J_{CP}$ = 5.4, CH₂P), 51.5 (COOCH₃), 52.2 (t, ${}^{3}J_{CP}$ = 7.3, CH₂N), 65.6 (t, ${}^{3}J_{CP}$ = 3.5, OCH₂), 172.3 (C=O); 1 H NMR (CDCl₃) δ : 0.90 (t, ${}^{3}J_{HH}$ = 7.3, 12H, CH₂CH₂CH₂CH₃), 1.30–1.43 (m, 8H, OCH₂CH₂CH₂), 1.55–1.70 (m, 8H, OCH₂CH₂), 2.50 (t, ${}^{3}J_{HH}$ = 7.2, 2H, CH₂C=O), 3.13 (t, ${}^{3}J_{HH}$ = 7.2, 2H, CH₂N), 3.17 (d, ${}^{2}J_{PH}$ = 8.3, 4H, CH₂P), 3.63 (s, 3H, COOCH₃), 3.96–4.10 (m, 8H, OCH₂); [M + H]⁺_{found} = 516.2845, C₂₂H₄₈NO₈P₂ requires 516.2848.

N,*N*-Bis(dibenzylyoxyphosphonylmethyl)-βalanine Methyl Ester (**5d**). Yield: 99% (1.10 g); ³¹P NMR (CDCl₃) δ: 25.4; ¹³C NMR (CDCl₃) δ: 32.8 (CH₂C=O), 50.4 (dd, ¹*J*_{CP} = 155.1, ³*J*_{CP} = 6.2, CH₂P), 51.5 (COOCH₃), 52.3 (t, ³*J*_{CP} = 7.3, CH₂N), 67.4 (t, ³*J*_{CP} = 3.4, OCH₂) 127.9 (C₃),* 128.3 (C₄), 128.5 (C₂),* 136.2 (t, ³*J*_{CP} = 2.9, C₁), 172.2 (C=O), *may be reversed; ¹H NMR (CDCl₃) δ: 2.42 (t, ³*J*_{HH} = 7.1, 2H, CH₂C=O), 3.12 (t, ³*J*_{HH} = 7.0, 2H, CH₂N), 3.21 (d, ²*J*_{PH} = 8.1, 4H, CH₂P), 3.57 (s, 3H, COOCH₃), 4.91–5.07 (m, 8H, OCH₂), 7.25–7.38 (m, 20H, ArH); [M + H]⁺_{found} = 652.2213, C₃₄H₄₀NO₈P₂ requires 652.2224.

N,*N*-*Bis*(*dimethoxyphosphonylmethyl*)-β-alanine Ethyl Ester (**6a**). Yield: 76% (0.47 g); ³¹P NMR (CDCl₃) δ: 27.0; ¹³C NMR (CDCl₃) δ: 14.1 (CH₂CH₃), 33.1 (CH₂C=O), 49.2 (dd, ¹J_{CP} = 156.0, ³J_{CP} = 5.8, CH₂P), 52.5 (t, ³J_{CP} = 7.6, CH₂N), 52.6 (t, ²J_{CP} = 3.3, OCH₃), 60.5 (OCH₂), 171.9 (C=O); ¹H NMR (CDCl₃) δ: 1.24 (t, ³J_{HH} = 7.4, 3H, OCH₂CH₃), 2.49 (t, ³J_{HH} = 7.0, 2H, CH₂C=O), 3.11 (t, ³J_{HH} = 7.0, 2H, CH₂N), 3.19 (d, ²J_{PH} = 8.6, 4H, CH₂P), 3.75 (d, 12H, ²J_{PH} = 10.4, OCH₃), 4.11 (q, 2H, OCH₂); $[M + H]^+_{found} =$ 362.1141, C₁₁H₂₆NO₈P₂ requires 362.1128.

N,N-Bis(diethoxyphosphonylmethyl)-β-alanine

Ethyl Ester (6b). Yield: 87% (0.66 g); ³¹P NMR (CDCl₃) *δ*: 24.6; *δ* [24] (CDCl₃) 24.2; ¹³C NMR (CDCl₃) δ : 14.0 (C(O)OCH₂CH₃), 16.3 (t, ³J_{CP} = 2.6, CH₂CH₃), 32.9 (CH₂C=O), 49.9 (dd, ${}^{1}J_{CP} = 155.5$, ${}^{3}J_{CP} = 5.7$, CH₂P), 52.2 (t, ${}^{3}J_{CP} = 7.5$, CH₂N), 60.2 $(C(O)OCH_2)$, 61.9 (t, ${}^2J_{CP} = 3.3$, CH_2CH_3), 171.8 (C=O); δ [24] (CDCl₃) 50.40 (dd, ¹*J*_{CP} = 154.8, ³*J*_{CP} = 6.0, CH₂P), 52.94 (t, ${}^{3}J_{CP}$ = 8.4, CH₂N), 171.73 (C=O); ¹H NMR (CDCl₃) δ : 1.26 (t, ³*J*_{HH} = 7.1, 3H, $C(O)OCH_2CH_3)$, 1.33 (t, ${}^{3}J_{HH} = 7.0$, 12H, CH_2CH_3), 2.53 (t, ${}^{3}J_{\text{HH}} = 7.1$, 2H, CH₂C=O), 3.14 (t, ${}^{3}J_{\text{HH}} =$ 7.0, 2H, CH₂N), 3.22 (d, ${}^{2}J_{PH} = 8.5$, 4H, CH₂P), 4.05-4.18 (m, 10H, OCH₂); δ [24] (CDCl₃) 3.25 (k, ${}^{3}J_{\rm HH} = 7.8, 2 {\rm H}, {\rm CH}_{2} {\rm N}$), 3.28 (d, ${}^{2}J_{\rm PH} = 9.0, 4 {\rm H}$, CH₂P); $[M + H]^+_{found} = 418.1757, C_{15}H_{34}NO_8P_2$ requires 418.1752.

N,*N*-*Bis*(*dibutoxyphosphonylmethyl*)-*β*-*alanine Ethyl Ester* (**6c**). Yield: 77% (0.69 g); ³¹P NMR (CDCl₃) δ: 24.8; ¹³C NMR (CDCl₃) δ: 13.5 (CH₂ CH₂CH₂CH₃), 14.1 (CH₂CH₃), 18.7 (CH₂CH₂CH₂CH₃), 32.6 (t, ³*J*_{CP} = 2.9, OCH₂CH₂), 33.2 (*C*H₂C=O), 49.9 (dd, ¹*J*_{CP} = 154.8, ³*J*_{CP} = 5.6, CH₂P), 52.3 (t, ³*J*_{CP} = 7.3, CH₂N), 60.4 (OCH₂CH₃), 65.7 (t, ³*J*_{CP} = 3.5, OCH₂CH₂), 171.9 (C=O); ¹H NMR (CDCl₃) δ: 0.92 (t, ³*J*_{HH} = 7.3, 12H, CH₂CH₂CH₂CH₃), 1.24 (t, ³*J*_{HH} = 7.2, 3H, OCH₂CH₃), 1.31–1.46 (m, 8H, OCH₂CH₂CH₂), 1.56– 1.71 (m, 8H, OCH₂CH₂), 2.50 (t, ³*J*_{HH} = 7.0, 2H, CH₂C=O), 3.13 (t, ³*J*_{HH} = 7.3, 2H, CH₂N), 3.19 (d, ²*J*_{PH} = 8.2, 4H, CH₂P), 3.98–4.17 (m, 10H, OCH₂); [M + H]⁺_{found} = 530.3069, C₂₃H₅₀NO₈P₂ requires 530.3062.

N,*N*-*Bis*(*dibenzylyoxyphosphonylmethyl*)-β*alanine Ethyl Ester* (**6d**). Yield: 91% (1.03 g); ³¹P NMR (CDCl₃) δ: 25.4; ¹³C NMR (CDCl₃) δ: 14.1 (OCH₂CH₃), 32.9 (CH₂C=O), 50.4 (dd, ¹*J*_{CP} = 155.0, ³*J*_{CP} = 5.8, CH₂P), 52.3 (t, ³*J*_{CP} = 7.3, CH₂N), 60.3 (OCH₂CH₃), 67.4 (t, ³*J*_{CP} = 3.4, OCH₂) 127.9 (C₃),* 128.3 (C₄), 128.5 (C₂),* 136.2 (t, ³*J*_{CP} = 2.9, C₁), 171.7 (C=O), *may be reversed; ¹H NMR (CDCl₃) δ: 1.19 (t, ³*J*_{HH} = 7.1, 3H, OCH₂CH₃), 2.41 (t, ³*J*_{HH} = 7.2, 2H, CH₂C=O), 3.12 (t, ³*J*_{HH} = 6.9, 2H, CH₂N), 3.21 (d, ²*J*_{PH} = 8.1, 4H, CH₂P), 4.04 (q, 2H, C(O)OCH₂), 4.88–5.09 (m, 8H, OCH₂), 7.26–7.33 (m, 20H, ArH); [M + H]⁺_{found} = 666.2374, C₃₅H₄₂NO₈P₂ requires 666.2380.

General Procedure for the Synthesis of N,N-Bis-(diphenylphosphinoylmethyl)- β -alanine (**7**) and N,N-Bis(diphenylphosphinoylmethyl)- β -alanine Esters (**8** and **9**)

A mixture of 0.85 mmol β -alanine or its esters (β -alanine: 0.08 g, β -alanine methyl ester: 0.09 g, or β -alanine ethyl ester: 0.10 g), 0.05 g (1.7 mmol) of paraformaldehyde, 0.34 g (1.7 mmol) of diphenylphosphine oxide in 3 mL of acetonitrile was heated at 100°C in a closed vial in the MW reactor for 1 h. The work-up was similar as above to provide products **7**, **8**, and **9** as oils.

N,*N*-bis(diphenylphosphinoylmethyl)- β -alanine (7). Yield: 61% (0.27 g); ³¹P NMR (CDCl₃) δ : 30.1; δ [25] (CDCl₃) 30.0; ¹³C NMR (CDCl₃) δ : 32.3 (CH₂C=O), 54.6 (t, ³*J*_{CP} = 6.7, CH₂N), 55.2 (dd, ¹*J*_{CP} = 82.4, ³*J*_{CP} = 6.5, CH₂P), 128.6 (d, ³*J*_{CP} = 12.0, C₃),* 131.1 (d, ³*J*_{CP} = 9.6, C₂),* 131.2 (d, ³*J*_{CP} = 97.9, C₁), 131.9 (C₄), 174.5 (C=O), *may be reversed; ¹H NMR (CDCl₃) δ : 2.47 (t, ³*J*_{HH} = 6.6, 2H, CH₂C=O), 3.23 (t, ³*J*_{HH} = 6.5, 2H, CH₂N), 3.76 (d, ²*J*_{PH} = 4.3, 4H, CH₂P), 7.32–7.78 (m, 20H, ArH); δ [25]* (CDCl₃) 2.53 (t, 2H, CH₂), 3.23 (s, 2H, CH₂N), 3.79 (s, 4H, CH₂P), 7.36–7.73 (m, 20H, ArH); [M + H]⁺_{found} = 518.1638, C₂₉H₂₉NO₄P₂ requires 518.1645.

N,*N*-Bis(diphenylphosphinoylmethyl)-β-alanine Methyl Ester (**8**). Yield: 89% (0.40 g); ³¹P NMR (CDCl₃) δ: 29.1; ¹³C NMR (CDCl₃) δ: 31.5 (CH₂C=O), 51.5 (COOCH₃), 53.9 (t, ³J_{CP} = 6.6, CH₂N), 55.6 (dd, ¹J_{CP} = 83.3, ³J_{CP} = 6.8, CH₂P), 128.4 (d, ³J_{CP} = 11.7, C₃),* 131.1 (d, ³J_{CP} = 9.3, C₂),* 131.7 (C₄), 131.9 (d, ³J_{CP} = 88.2, C₁), 172.8 (C=O), *may be reversed; ¹H NMR (CDCl₃) δ: 1.50–1.62 (m, 2H, CH₂CH₂CH₂), 1.88 (t, ³J_{HH} = 7.4, 2H, CH₂C=O), 2.98 (t, ³J_{HH} = 6.4, 2H, CH₂N), 3.59 (s, 3H, COOCH₃), 3.72 (d, ²J_{PH} = 5.8, 4H, CH₂P), 7.34–7.78 (m, 20H, ArH); [M + H]⁺_{found} = 532.1806, C₃₀H₃₂NO₄P₂ requires 532.1811.

N,*N*-*Bis*(*diphenylphosphinoylmethyl*)-β-alanine *Ethyl Ester* (**9**). Yield: 85% (0.40 g); ³¹P NMR (CDCl₃) δ: 29.2; ¹³C NMR (CDCl₃) δ: 14.1 (OCH₂CH₃), 31.6 (*C*H₂C=O), 53.8 (t, ³J_{CP} = 7.0, CH₂N), 55.6 (dd, ¹J_{CP} = 83.3, ³J_{CP} = 7.0, CH₂P), 60.4 (OCH₂CH₃), 128.4 (d, ³J_{CP} = 11.7, C₃),* 131.1 (d, ³J_{CP} = 9.4, C₂),* 131.7 (C₄), 131.9 (d, ³J_{CP} = 87.6, C₁), 172.4 (C=O), *may be reversed; ¹H NMR (CDCl₃) δ: 1.15 (t, ³J_{HH} = 7.2, 3H, OCH₂CH₃), 2.39 (t, ³J_{HH} = 6.9, 2H, CH₂C=O), 3.32 (t, ³J_{HH} = 6.7, 2H, CH₂N), 3.76 (d, ²J_{PH} = 5.81, 4H, CH₂P), 3.98 (q, 2H, C(O)OCH₂), 7.33–7.79 (m, 20H, ArH); [M + H]⁺_{found} = 546.1960, C₃₁H₃₄NO₄P₂ requires 546.1958.

General Procedure for the Preparation of Bis(>P(O)CH₂)- γ -aminobutyric Acids (**13**) and Bis(>P(O)CH₂)- γ -aminobutyric Acid Esters (**14** and **15**)

A mixture of 1.7 mmol γ -aminobutyric acid or its esters (γ -aminobutyric acid: 0.18 g, γ -aminobutyric acid methyl ester: 0.20 g, or γ -aminobutyric acid ethyl ester: 0.22 g), 0.10 g (3.4 mmol) of paraformaldehyde, and 3.4 mmol of the >P(O)H species (dimethyl phosphite: 0.31 mL, diethyl phosphite: 0.44 mL, dibutyl phosphite: 0.67 mL, and dibenzyl phosphite: 0.75 mL) was heated at 100°C in a vial in the MW reactor equipped with a pressure controller for 1 h. Then, the water formed was removed in a vacuum. Column chromatography (silica gel 3% methanol in dichloromethane) of the residue afforded the products (**13a–d**, **14a–-d**, **15a–d**) as oils. The following products were thus prepared.

N,N-Bis(dimethoxyphosphonylmethyl)-\gammaaminobutyric Acid (**13a**). Yield: 79% (0.47 g); ³¹P NMR (CDCl₃) δ: 24.9; δ [23] (CDCl₃) 30.7; ¹³C NMR (CDCl₃) δ : 22.6 (CH₂CH₂CH₂N), 31.2 $(CH_2C=0)$, 49.4 (dd, ${}^{1}J_{CP} = 158.5$, ${}^{3}J_{CP} = 7.3$, CH_2P), 52.7 (t, ${}^{3}J_{CP} = 3.4$, OCH₃), 56.0 (t, ${}^{2}J_{CP} = 7.5$, CH₂N), 176.1 (C=O); δ [23] (CDCl₃) 22.6 (CH₂CH₂CH₂N), 31.1 (*C*H₂C=O), 49.3 (dd, ${}^{1}J_{CP} = 158.0$, ${}^{3}J_{CP} = 7.3$, CH₂P), 52.8 (d, ${}^{2}J_{CP} = 7.2$, OCH₃), 56.0 (t, ${}^{2}J_{CP} =$ 7.5, CH₂N), 176.1 (C=O); ¹H NMR (CDCl₃) δ: 1.79 (t, ${}^{3}J_{HH} = 7.2$, 2H, CH₂CH₂CH₂N), 2.41 (t, ${}^{3}J_{HH} =$ 7.4, 2H, CH₂C=O), 2.83 (t, ${}^{3}J_{HH} = 6.8$, 2H, CH₂N), 3.16 (d, ${}^{2}J_{PH} = 8.9$, 4H, CH₂P), 3.79 (d, 12H, ${}^{2}J_{PH} =$ 10.6, OCH₃); δ [23] (CDCl₃) 1.74 (q, ³*J*_{HH} = 7.1, 2H, $CH_2CH_2CH_2N$), 2.36 (t, ${}^{3}J_{HH} = 7.1$, 2H, $CH_2C=0$), 2.78 (t, ${}^{3}J_{HH} = 7.1$, 2H, CH₂N), 3.10 (d, ${}^{2}J_{PH} =$ 8.8, 4H, CH₂P), 3.74 (d, 12H, ${}^{2}J_{PH} = 10.7$, OCH₃); $[M + H]^+_{found} = 348.0971, C_{10}H_{24}NO_8P_2$ requires 348.0972.

N,N-Bis(diethoxyphosphonylmethyl)-y-aminobutyric Acid (13b). Yield: 76% (0.52 g); ³¹P NMR (CDCl₃) δ : 25.9; δ [24] (CDCl₃) 22.2; ¹³C NMR $(CDCl_3)$ δ : 16.3 (t, ${}^{3}J_{CP} = 2.8$, CH_2CH_3), 22.6 $(CH_2CH_2CH_2N)$, 31.2 $(CH_2C=0)$, 50.0 $(dd, {}^{1}J_{CP} =$ 157.6, ${}^{3}J_{CP} = 7.0$, CH₂P), 55.8 (t, ${}^{3}J_{CP} = 7.3$, CH₂N), 62.0 (t, ${}^{2}J_{CP} = 3.4$, OCH₂), 175.8 (C=O); δ [24] (CDCl₃) 49.56 (dd, ${}^{1}J_{CP} = 156.4$, ${}^{3}J_{CP} = 7.1$, CH₂P), 55.50 (t, ${}^{3}J_{CP} = 7.5$), 175.14 (C=O); ¹H NMR (CDCl₃) δ: 1.25 (t, ${}^{3}J_{HH}$ = 7.0, 12H, CH₂CH₃), 1.71 (t, ${}^{3}J_{HH}$ = 7.0, 2H, $CH_2CH_2CH_2N$), 2.31 (t, ${}^{3}J_{HH}$ = 7.0, 2H, CH₂C=O), 2.76 (t, ${}^{3}J_{HH} = 6.5$, 2H, CH₂N), 3.08 (d, ${}^{2}J_{\rm PH} = 8.9, 4H, CH_{2}P), 4.01-4.16$ (m, 8H, OCH₂); δ [24] (CDCl₃) 2.61 (t, ³J_{HH} = 6.6, 2H, CH₂N), 2.94 $(d, {}^{2}J_{PH} = 8.8, 4H, CH_{2}P); [M + H]^{+}_{found} = 404.1592,$ C₁₄H₃₂NO₈P₂ requires 404.1598.

N,N-Bis(dibutoxyphosphonylmethyl)-y-amino-

N,*N*-*BIS*(*abballoxyphosphohylmethyl*)-*p*-*amhobutyric Acid* (**13c**). Yield: 77% (0.68 g); ³¹P NMR (CDCl₃) δ : 25.7; ¹³C NMR (CDCl₃) δ : 13.5 (CH₂ CH₂CH₂CH₃), 18.7 (CH₂CH₂CH₂CH₃), 22.9 (CH₂CH₂CH₂CH₂), 31.5 (CH₂C=O), 32.5 (t, ³J_{CP} = 2.8, OCH₂CH₂), 50.0 (dd, ¹J_{CP} = 156.9, ³J_{CP} = 6.6, CH₂P), 55.7 (t, ³J_{CP} = 6.9, CH₂N), 65.8 (t, ³J_{CP} = 3.5, OCH₂CH₂), 176.1 (C=O); ¹H NMR (CDCl₃) δ : 0.93 (t, ³J_{HH} = 7.3, 12H, CH₂CH₂CH₂CH₃), 1.34–1.45 (m, 8H, OCH₂CH₂CH₂), 1.57–1.70 (m, 8H, OCH₂CH₂), 1.79 (t, ³J_{HH} = 6.9, 2H, CH₂CH₂CH₂N), 2.40 (t, ³J_{HH} = 7.3, 2H, CH₂C=O), 2.85 (t, ³J_{HH} = 6.0, 2H, CH₂N), 3.15 (d, ²J_{PH} = 8.5, 4H, CH₂P), 4.01–4.15 (m, 8H, OCH₂); [M + H]⁺_{found} = 516.2844, C₂₂H₄₈NO₈P₂ requires 516.2850.

N,N-Bis(dibenzylyoxyphosphonylmethyl)-\gamma-aminobutyric Acid (13d). Yield: 81% (0.90 g); ³¹P NMR (CDCl₃) δ : 26.5; ¹³C NMR (CDCl₃) δ : 22.7

(CH₂CH₂CH₂), 31.3 (CH₂C=O), 50.5 (dd, ${}^{1}J_{CP} =$ 157.2, ${}^{3}J_{CP} =$ 7.2, CH₂P), 55.8 (t, ${}^{3}J_{CP} =$ 7.0, CH₂N), 67.6 (t, ${}^{3}J_{CP} =$ 3.4, OCH₂) 128.0 (C₃),* 128.4 (C₄), 128.5 (C₂),* 136.0 (t, ${}^{3}J_{CP} =$ 2.9, C₁), 176.2 (C=O), *may be reversed; 1 H NMR (CDCl₃) δ : 1.69 (t, ${}^{3}J_{HH} =$ 6.9, 2H, CH₂CH₂CH₂), 2.29 (t, ${}^{3}J_{HH} =$ 7.3, 2H, CH₂C=O), 2.78 (t, ${}^{3}J_{HH} =$ 6.2, 2H, CH₂N), 3.12 (d, ${}^{2}J_{PH} =$ 8.3, 4H, CH₂P), 4.90–5.01 (m, 8H, OCH₂), 7.23–7.30 (m, 20H, ArH); [M + H]⁺_{found} = 652.2211, C₃₄H₄₀NO₈P₂ requires 652.2224.

N,*N*-*Bis*(*dimethoxyphosphonylmethyl*)-γ-*aminobutyric Acid Methyl Ester* (**14a**). Yield: 86% (0.52 g); ³¹P NMR (CDCl₃) δ: 24.7; ¹³C NMR (CDCl₃) δ: 22.5 (CH₂CH₂CH₂), 30.9 (CH₂C=O), 49.2 (dd, ¹*J*_{CP} = 157.9, ³*J*_{CP} = 7.1, CH₂P), 51.5 (COOCH₃), 52.6 (t, ²*J*_{CP} = 6.9, OCH₃), 55.9 (t, ³*J*_{CP} = 7.6, CH₂N), 173.8 (C=O); ¹H NMR (CDCl₃) δ: 1.65–1.82 (m, 2H, CH₂CH₂CH₂), 2.40 (t, ³*J*_{HH} = 7.4, 2H, CH₂C=O), 2.82 (t, ³*J*_{HH} = 6.7, 2H, CH₂N), 3.16 (d, ²*J*_{PH} = 9.0, 4H, CH₂P), 3.67 (s, 3H, COOCH₃), 3.78 (d, 12H, ²*J*_{PH} = 10.6, OCH₃); [M + H]⁺_{found} = 362.1126, C₁₁H₂₆NO₈P₂ requires 362.1128.

N,N-Bis(diethoxyphosphonylmethyl)-y-amino-

butyric Acid Methyl Ester (14b). Yield: 89% (0.63 g); ³¹P NMR (CDCl₃) δ : 26.0; δ [24] (CDCl₃) 24.4; ¹³C NMR (CDCl₃) δ : 16.4 (t, ³ $J_{CP} = 2.8$, CH₂CH₃), 22.6 (CH₂CH₂CH₂), 31.0 (CH₂C=O), 50.0 (dd, ¹J_{CP}) = 157.1, ${}^{3}J_{CP}$ = 6.9, CH₂P), 51.4 (COOCH₃), 55.7 (t, ${}^{3}J_{CP} = 7.7$, CH₂N), 61.9 (t, ${}^{2}J_{CP} = 3.4$, OCH₂), 173.8 (C=O); δ [24] (CDCl₃) 50.45 (dd, ¹*J*_{CP} = 156.9, ³*J*_{CP} = 7.1, CH₂P), 56.18 (t, ${}^{3}J_{CP}$ = 8.3, CH₂N), 173.07 (C=O); ¹H NMR (CDCl₃) δ : 1.30 (t, ³*J*_{HH} = 7.0, 12H, CH₂CH₃), 1.70–1.81 (m, 2H, CH₂CH₂CH₂), 2.37 (t, ${}^{3}J_{\text{HH}} = 7.4, 2\text{H}, \text{CH}_{2}\text{C=0}, 2.81 \text{ (t, } {}^{3}J_{\text{HH}} = 6.6, 2\text{H},$ CH₂N), 3.12 (d, ${}^{2}J_{PH} = 8.9$, 4H, CH₂P), 3.64 (s, 3H, COOCH₃), 4.05–4.14 (m, 8H, OCH₂); δ [24] (CDCl₃) 3.18 (d, ${}^{2}J_{PH} = 9.1$, 4H, CH₂P), 3.27 (k, ${}^{3}J_{HH} = 6.7$, 2H, CH₂N); $[M + H]^+_{found} = 418.1749, C_{15}H_{34}NO_8P_2$ requires 418.1754.

N,N-Bis(dibutoxyphosphonylmethyl)-y-amino-

butyric Acid Methyl Ester (14c). Yield: 84% (0.76 g); ³¹P NMR (CDCl₃) δ : 25.7; ¹³C NMR (CDCl₃) δ : 13.5 (CH₂ CH₂CH₂CH₃), 18.7 (CH₂CH₂CH₂CH₃), 22.7 (CH₂CH₂CH₂CH₂N), 31.1 (CH₂C=O), 32.5 (t, ³J_{CP} = 2.9, OCH₂CH₂), 49.8 (dd, ¹J_{CP} = 156.1, ³J_{CP} = 6.6, CH₂P), 51.4 (COOCH₃), 55.7 (t, ³J_{CP} = 7.5, CH₂N), 65.4–65.7 (m, OCH₂CH₂), 173.9 (C=O); ¹H NMR (CDCl₃) δ : 0.89 (t, ³J_{HH} = 7.3, 12H, CH₂CH₂CH₂CH₃), 1.29– 1.42 (m, 8H, OCH₂CH₂CH₂), 1.54–1.68 (m, 8H, OCH₂CH₂), 1.74 (t, ³J_{HH} = 7.2, 2H, CH₂CH₂CH₂CH₂N), 2.34 (t, ³J_{HH} = 7.4, 2H, CH₂C=O), 2.78 (t, ³J_{HH} = 6.7, 2H, CH₂N), 3.10 (d, ${}^{2}J_{PH} = 8.5$, 4H, CH₂P), 3.62 (s, 3H, COOCH₃), 3.96–4.09 (m, 8H, OCH₂); [M + H]⁺_{found} = 530.2998, C₂₃H₅₀NO₈P₂ requires 530.3006.

N,*N*-*Bis*(*dibenzylyoxyphosphonylmethyl*)-γaminobutyric Acid Methyl Ester (**14d**). Yield: 88% (1.0 g); ³¹P NMR (CDCl₃) δ: 26.0; ¹³C NMR (CDCl₃) δ: 22.5 (CH₂CH₂CH₂), 31.0 (CH₂C=O), 50.4 (dd, ¹*J*_{CP} = 156.4, ³*J*_{CP} = 7.1, CH₂P), 51.4 (COOCH₃), 55.7 (t, ³*J*_{CP} = 7.4, CH₂N), 67.2–67.5 (m, OCH₂), 127.9 (C₃),* 128.3 (C₄), 128.5 (C₂),* 136.2 (t, ³*J*_{CP} = 2.9, C₁), 173.7 (C=O), *may be reversed; ¹H NMR (CDCl₃) δ: 1.71 (t, ³*J*_{HH} = 7.1, 2H, CH₂CH₂CH₂), 2.27 (t, ³*J*_{HH} = 7.5, 2H, CH₂C=O), 2.81 (t, ³*J*_{HH} = 6.7, 2H, CH₂N), 3.17 (d, ²*J*_{PH} = 8.6, 4H, CH₂P), 4.95–5.20 (m, 8H, OCH₂), 7.28–7.32 (m, 20H, ArH); [M + H]⁺_{found} = 666.2383, C₃₅H₄₂NO₈P₂ requires 666.2380.

N,*N*-*Bis*(*dimethoxyphosphonylmethyl*)-γ-*aminobutyric Acid Ethyl Ester* (**15a**). Yield: 74% (0.47 g); ³¹P NMR (CDCl₃) δ: 24.7; ¹³C NMR (CDCl₃) δ: 14.1 (CH₂CH₃), 22.5 (CH₂CH₂CH₂C), 31.2 (CH₂C=O), 49.2 (dd, ¹*J*_{CP} = 157.8, ³*J*_{CP} = 7.1, CH₂P), 52.5 (t, ²*J*_{CP} = 3.4, OCH₃), 55.9 (t, ³*J*_{CP} = 7.7, CH₂N), 60.2 (OCH₂), 173.3 (C=O); ¹H NMR (CDCl₃) δ: 1.20 (t, ³*J*_{HH} = 7.1, 3H, OCH₂CH₃), 1.67–1.79 (m, 2H, CH₂CH₂CH₂), 2.33 (t, ³*J*_{HH} = 7.3, 2H, CH₂C=O), 2.76 (t, ³*J*_{HH} = 6.7, 2H, CH₂N), 3.11 (d, ²*J*_{PH} = 9.0, 4H, CH₂P), 3.73 (d, 12H, ²*J*_{PH} = 10.5, OCH₃), 4.11 (q, 2H, OCH₂); [M + H]⁺_{found} = 376.1276, C₁₂H₂₈NO₈P₂ requires 376.1285.

N,*N*-Bis(diethoxyphosphonylmethyl)- γ -aminobutyric Acid Ethyl Ester (**15b**). Yield: 96% (0.70 g); ³¹P NMR (CDCl₃) δ : 24.9; ¹³C NMR (CDCl₃) δ : 14.1 (C(O)OCH₂CH₃), 16.4 (t, ³*J*_{CP} = 2.9, CH₂CH₃), 22.6 (CH₂CH₂CH₂CH₂), 31.3 (CH₂C=O), 50.0 (dd, ¹*J*_{CP} = 156.9, ³*J*_{CP} = 6.9, CH₂P), 55.8 (t, ³*J*_{CP} = 7.8, CH₂N), 60.2 (C(O)OCH₂), 61.8 (t, ²*J*_{CP} = 3.4, CH₂CH₃),173.5 (C=O); ¹H NMR (CDCl₃) δ : 1.25 (t, ³*J*_{HH} = 7.1, 3H, C(O)OCH₂CH₃), 1.33 (t, ³*J*_{HH} = 7.0, 12H, CH₂CH₃), 1.75–1.83 (m, 2H, CH₂CH₂CH₂), 2.38 (t, ³*J*_{HH} = 7.4, 2H, CH₂C = O), 2.84 (t, ³*J*_{HH} = 6.7, 2H, CH₂N), 3.15 (d, ²*J*_{PH} = 8.8, 4H, CH₂P), 4.07–4.17 (m, 10H, OCH₂); [M + H]⁺_{found} = 432.1919, C₁₆H₃₆NO₈P₂ requires 432.1911.

N,*N*-*Bis*(*dibutoxyphosphonylmethyl*)-γ-*aminobutyric Acid Ethyl Ester* (**15c**). Yield: 79% (0.73 g); ³¹P NMR (CDCl₃) δ: 25.6; ¹³C NMR (CDCl₃) δ: 13.5 (CH₂ CH₂CH₂CH₃), 14.2 (OCH₂CH₃), 18.7 (CH₂CH₂CH₂CH₃), 22.7 (CH₂CH₂CH₂N), 31.4 (CH₂C=O), 32.6 (t, ³J_{CP} = 2.9, OCH₂CH₂), 49.8 (dd, ${}^{1}J_{CP} = 156.0$, ${}^{3}J_{CP} = 6.4$, CH₂P), 55.7 (t, ${}^{3}J_{CP} = 7.3$, CH₂N), 60.1 (OCH₂CH₃), 65.5 (t, ${}^{3}J_{CP} = 3.5$, OCH₂CH₂), 173.4 (C=O); ¹H NMR (CDCl₃) δ : 0.92 (t, ${}^{3}J_{HH} = 7.2$, 12H, CH₂CH₂CH₂CH₃), 1.23 (t, ${}^{3}J_{HH} = 7.0$, 3H, OCH₂CH₃), 1.33–1.42 (m, 8H, OCH₂CH₂CH₂CH₂), 1.57–1.68 (m, 8H, OCH₂CH₂), 1.77 (t, ${}^{3}J_{HH} = 7.1$, 2H, CH₂CH₂CH₂N), 2.35 (t, ${}^{3}J_{HH} = 7.3$, 2H, CH₂C=O), 2.81 (t, ${}^{3}J_{HH} = 6.6$, 2H, CH₂N), 3.13 (d, ${}^{2}J_{PH} = 8.7$, 4H, CH₂P), 4.00–4.13 (m, 10H, OCH₂); [M + H]⁺_{found} = 544.3165, C₂₄H₅₂NO₈P₂ requires 544.3163.

N,N-Bis(dibenzylyoxyphosphonylmethyl)-y-

aminobutyric Acid Ethyl Ester (**15d**). Yield: 97% (1.1 g); ³¹P NMR (CDCl₃) δ : 26.4; ¹³C NMR (CDCl₃) δ : 14.1 (OCH₂CH₃), 22.5 (CH₂CH₂CH₂CH₂), 31.2 (CH₂C=O), 50.4 (dd, ¹J_{CP} = 156.4, ³J_{CP} = 7.0, CH₂P), 55.7 (t, ³J_{CP} = 7.4, CH₂N), 60.1 (OCH₂CH₃), 67.3 (t, ³J_{CP} = 3.4, OCH₂) 127.8 (C₃),* 128.2 (C₄), 128.4 (C₂),* 136.2 (t, ³J_{CP} = 2.9, C₁), 173.2 (C=O), *may be reversed; ¹H NMR (CDCl₃) δ : 1.21 (t, ³J_{HH} = 7.1, 3H, OCH₂CH₃), 1.69 (t, ³J_{HH} = 7.1, 2H, CH₂CH₂CH₂), 2.23 (t, ³J_{HH} = 7.5, 2H, CH₂C=O), 2.79 (t, ³J_{HH} = 6.6, 2H, CH₂N), 3.16 (d, ²J_{PH} = 8.9, 4H, CH₂P), 4.07 (q, 2H, C(O)OCH₂), 4.90–5.06 (m, 8H, OCH₂), 7.23–7.34 (m, 20H, ArH); [M + H]⁺_{found} = 680.2532, C₃₆H₄₄NO₈P₂ requires 680.2537.

General Procedure for the Synthesis of N,N-Bis-(diphenylphosphinoylmethyl)- γ -aminobutyric Acid (**16**) and N,N-Bis(diphenylphosphinoylmethyl)- γ -aminobutyric Acid Esters (**17** and **18**)

A mixture of 0.85 mmol γ -aminobutyric acid or its esters (γ -aminobutyric acid: 0.09 g, γ aminobutyric acid methyl ester: 0.10 g, or γ aminobutyric acid ethyl ester: 0.11 g), 0.05 g (1.7 mmol) of paraformaldehyde, 0.34 g (1.7 mmol) of diphenylphosphine oxide in 3 mL of acetonitrile was heated at 100°C in a closed vial in the MW reactor for 1 h. The work-up was similar as above to provide products **10**, **11**, and **12** as oils.

N,N-Bis(diphenylphosphinoylmethyl)-y-amino-

butyric Acid (16). Yield: 60% (0.27 g); ³¹P NMR (CDCl₃) δ : 30.2; δ [25] (CDCl₃) 30.0; ¹³C NMR (CDCl₃) δ : 21.6 (CH₂CH₂CH₂), 31.1 (CH₂C=O), 55.4 (dd, ¹J_{CP} = 84.6, ³J_{CP} = 7.6, CH₂P), 57.3 (t, ³J_{CP} = 6.8, CH₂N), 128.5 (d, ³J_{CP} = 11.8, C₃),* 130.9 (d, ³J_{CP} = 9.4, C₂),* 131.0 (d, ³J_{CP} = 98.6, C₁), 131.9 (C₄), 175.7 (C=O), *may be reversed; ¹H NMR (CDCl₃) δ : 1.56–1.69 (m, 2H, CH₂CH₂CH₂), 2.10 (t, ³J_{HH} = 7.1, 2H, CH₂C=O), 2.94 (t, ³J_{HH} = 6.4, 2H, CH₂N), 3.72 (d, ${}^{2}J_{PH} = 5.4$, 4H, CH₂P), 7.33–7.78 (m, 20H, ArH); δ [25]* (CDCl₃) 1.69 (m, 2H, CH₂), 2.15 (t, 2H, CH₂), 2.97 (t, 2H, CH₂N), 3.76 (d, ${}^{2}J_{PH} = 3.6$, 4H, CH₂P), 7.32–7.86 (m, 20H, ArH); [M + H]+_{found} = 532.1801, C₃₀H₃₂NO₄P₂ requires 532.1801.

N,*N*-*Bis*(*diphenylphosphinoylmethyl*)-*γ*-*aminobutyric Acid Methyl Ester* (**17**). Yield: 94% (0.44 g); ³¹P NMR (CDCl₃) δ: 29.5; ¹³C NMR (CDCl₃) δ: 21.8 (CH₂CH₂CH₂C), 30.7 (CH₂C=O), 51.3 (COOCH₃), 55.7 (dd, ¹*J*_{CP} = 84.8, ³*J*_{CP} = 7.8, CH₂P), 57.3 (t, ³*J*_{CP} = 7.2, CH₂N), 128.4 (d, ³*J*_{CP} = 11.7, C₃),* 131.0 (d, ³*J*_{CP} = 9.2, C₂),* 131.7 (C₄), 131.8 (d, ³*J*_{CP} = 84.8, C₁), 174.0 (C=O), *may be reversed; ¹H NMR (CDCl₃) δ: 1.50–1.62 (m, 2H, CH₂CH₂CH₂), 1.88 (t, ³*J*_{HH} = 7.4, 2H, CH₂C=O), 2.98 (t, ³*J*_{HH} = 6.4, 2H, CH₂N), 3.59 (s, 3H, COOCH₃), 3.72 (d, ²*J*_{PH} = 5.8, 4H, CH₂P), 7.34–7.78 (m, 20H, ArH); [M + H]+_{found} = 546.1945, C₃₁H₃₄NO₄P₂ requires 546.1958.

N,*N*-*Bis*(*diphenylphosphinoylmethyl*)-*γ*-*aminobutyric Acid Ethyl Ester* (**18**). Yield: 80% (0.38 g); ³¹P NMR (CDCl₃) δ: 29.2; ¹³C NMR (CDCl₃) δ: 14.2 (OCH₂*C*H₃), 21.8 (CH₂*C*H₂CH₂), 31.1 (*C*H₂C=O), 55.8 (dd, ¹*J*_{CP} = 84.9, ³*J*_{CP} = 7.8, CH₂P), 57.5 (t, ³*J*_{CP} = 6.8, CH₂N), 60.0 (OCH₂CH₃), 128.4 (d, ³*J*_{CP} = 11.7, C₃),* 131.1 (d, ³*J*_{CP} = 9.2, C₂),* 131.6 (C₄), 132.0 (d, ³*J*_{CP} = 97.9, C₁), 173.6 (C=O), *may be reversed; ¹H NMR (CDCl₃) δ: 1.22 (t, ³*J*_{HH} = 4.6, 3H, OCH₂CH₃), 1.51–1.66 (m, 2H, CH₂CH₂CH₂), 1.90 (t, ³*J*_{HH} = 7.6, 2H, CH₂C=O), 3.00 (t, ³*J*_{HH} = 6.7, 2H, CH₂N), 3.72 (d, ²*J*_{PH} = 6.0, 4H, CH₂P), 4.05 (q, 2H, C(O)OCH₂), 7.32–7.85 (m, 20H, ArH); [M + H]⁺_{found} = 560.2111, C₃₂H₃₆NO₄P₂ requires 560.2114.

N-Diphenylphosphinoylmethyl)pyrrolodin-2-one (**19**). ³¹P NMR (CDCl₃) δ : 30.3; ¹³C NMR (CDCl₃) δ : 17.9 (C₄), 29.9 (C₃=O), 43.3 (d, $J_{CP} = 43.3$, CH₂P), 48.5 (C₅N), 128.7 (d, ³ $J_{CP} = 11.8$, C₃'),* 130.7 (d, ³ $J_{CP} = 98.4$, C₁'), 130.9 (d, ³ $J_{CP} = 9.7$, C₂'),* 132.2 (d, ³ $J_{CP} = 2.8$, C₄'), 174.9 (d, ³ $J_{CP} = 2.7$, C=O), *may be reversed; ¹H NMR (CDCl₃) δ : 1.83–1.92 (m, 2H, C₄H), 2.20 (t, ³ $J_{HH} = 8.4$, 2H, C₃H), 3.65 (t, ³ $J_{HH} = 7.0$, 2H, C₅H), 4.23 (d, ² $J_{PH} = 5.6$, 2H, CH₂P), 7.44–7.88 (m, 10H, ArH); δ [29] (CDCl₃) 1.9 (m, 2H, CH₂), 2.2 (t, ³ $J_{HH} = 6.2$, 2H, CH₂), 3.6 (t, ³ $J_{HH} = 6.9$, 2H, CH₂), 4.2 (d, ² $J_{PH} = 5.7$, 2H, CH₂P), 7.1–8.0 (m, 10H, ArH); [M + H]⁺_{found} = 300.1146, C₁₇H₁₉NO₂P requires 300.1153.

REFERENCES

- Kabachnik, M. I.; Medved, T. Y. Dokl Akad Nauk SSSR 1952, 83, 689–692.
- [2] Fields, E. K. J Am Chem Soc 1952, 74, 1528–1531.

- [3] Kukhar, V. P.; Hudson, H. R. (Eds.); Aminophosphonic and Aminophosphinic Acids: Chemistry and Biological Activity; Wiley: Chichester, UK, 2000.
- [4] Cherkasov, R. A.; Galkin, V. I. Russ Chem Rev 1998, 67, 857–882.
- [5] Keglevich, G.; Bálint, E. Molecules 2012, 17, 12821– 12835.
- [6] Zefirov, N. S.; Matveeva, E. D. ARKIVOC 2008, 1-17.
- [7] Kafarski, P.; Lejczak, B. Curr Med Chem Anti-Cancer Agents 2001, 1, 301–312.
- [8] Mucha, A.; Kafarski, P.; Berlicki, L. J Med Chem 2011, 54, 5955–5980.
- [9] Matveeva, E. D.; Podrugina, T. A.; Tishkovskaya, E. V.; Tomilova, L. G.; Zefirov, N. S. Synlett 2003, 2321– 2324.
- [10] Ranu, B. C.; Hajra, A.; Jana, U. Org Lett 1999, 1, 1141–1143.
- [11] Keglevich, G.; Szekrényi, A. Lett Org Chem 2008, 5, 616–622.
- [12] Cherkasov, R. A.; Garifzyanov, A. R.; Koshkin, S. A. Phosphorus, Sulfur, Silicon 2011, 186, 782–784.
- [13] Naydenova, E. D.; Todorov, P. T.; Topashka-Ancheva, M. N.; Momekov, G. Ts.; Yordanova, T. Z.; Konstantinov, S. M.; Troev, K. D. Eur J Med Chem 2008, 43, 1199–1205.
- [14] Todorov, P. T.; Pavlov, N. D.; Shivachev, B. L.; Petrova, R. N.; Martinez, J. Naydenova, E. D.; Calmes, M. Heteroatom Chem 2012, 23, 123–130.
- [15] Cherkasov, R. A.; Garifzyanov, A. R.; Talan, A. S.; Davletshin, R. R.; Kurnosova, N. V. Russ J Gen Chem 2009, 79, 1480–1494.

- [16] Keglevich, G.; Szekrényi, A.; Szöllősy, L.; Drahos, L. Synth Commun 2011, 41, 2265–2272.
- [17] Bálint, E.; Fazekas, E.; Pintér, G.; Szöllősy, Á.; Holczbauer, T.; Czugler, M.; Drahos, L.; Körtvélyesi, T.; Keglevich, G. Curr Org Chem 2012, 16, 547–554.
- [18] Bálint, E.; Fazekas, E.; Pongrácz, P.; Kollár, L.; Drahos, L.; Holczbauer, T.; Czugler, M.; Keglevich, G. J Organomet Chem 2012, 717, 75–82.
- [19] Natchev, I. A. Phosphorus, Sulfur, Silicon 1988, 37, 133.
- [20] Rogers, T. E. US Patent 2013/0066086 A1.
- [21] Chougrani, K.; Niel, G.; Boutevin, B.; Ghislain, D. Beilstein J Org Chem 2011, 7, 364–368.
- [22] Bálint, E.; Fazekas, E.; Drahos, L.; Keglevich, G. Heteroatom Chem 2013, 24, 510–515.
- [23] Majoral, J.-P.; Caminade, A.-M. J. J.; Fournie, J.-J.; Griffe, M.; Poupot-Marsan, M.; Turrin, C.-O. US Patent 2009/0142316 A1.
- [24] Prishchenko, A. A.; Livantsov, M. V.; Novikova, O. P.; Livantsova, L. I.; Petrosyan, V. S. Heteroatom Chem 2010, 21, 430–440.
- [25] Elsegood, M. R. J.; Noble, T. A.; Talib, S.; Smith, M. B. Phosphorus, Sulfur, Silicon 2013, 188, 121–127.
- [26] Kranjc, K.; Kočevar, M. Curr Org Chem 2010, 14, 1050–1074.
- [27] Keglevich, G.; Kiss, N. Z.; Mucsi, Z.; Körtvélyesi, T. Org Biomol Chem 2012, 10, 2011–2018.
- [28] Blandé-Font, A. Tetrahedron Lett 1980, 21, 2443–2446.
- [29] Couture, A.; Deniau, E.; Grandclaudon, P. Synth Commun 1992, 22, 2381–2392.